You just read:

Lynparza® (olaparib) Phase III SOLO-2 trial demonstrates significant progression-free survival benefit for women with BRCA-mutated ovarian cancer

News provided by

AstraZeneca Canada Inc.

Mar 16, 0001, 15:59 ET